India Oral Anti-Diabetic Drug - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the India oral anti-diabetic drug market size was valued at USD 1.76 billion in 2025 and estimated to grow from USD 1.82 billion in 2026 to reach USD 2.16 billion by 2031, at a CAGR of 3.46% during the forecast period (2026-2031).

This report is Segmented by Drug Class (Biguanides, Sulfonylureas, Meglitinides, and More), Age Group (Adults, Pediatric, and Geriatric), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The Market and Forecasts are Provided in Terms of Value (USD).

India Oral Anti-Diabetic Drug Market Trends and Insights

Rising Prevalence of T2DM & Pre-Diabetes

India hosts 77 million individuals with diabetes and projections indicate 134 million cases by 2045. Urban blood-glucose screening campaigns reveal that 49.43% of tested adults show abnormal values and 27.18% already meet diabetic thresholds. Lucknow prevalence data record 15.8% urban versus 11.7% rural incidence, underscoring market opportunities beyond metros. Annual diabetes-linked healthcare costs exceed USD 5 billion, and poorer households devote up to 23.7% of income to disease management. These epidemiological realities drive consistent therapy demand, though the India oral anti-diabetic drug market grows at a measured pace given rising generic penetration and price caps.

Patent Expiries Accelerating Generic Launches

Empagliflozin's March 2025 patent cliff spurred an influx of 147 generic brands, doubling market participants within a month. Generic tablets retail at INR 5.49 compared with the innovator's INR 59, unleashing 80-90% price erosion. Upcoming expiries-Semaglutide (Jan 2026) and Sitagliptin/Metformin FDCs (Jul 2029)-promise sustained openings for domestic formulators. Multinationals respond by bundling cardiovascular-renal claims and co-packaged devices to justify premium positioning. Rapid genericisation democratises access while rewiring competitive dynamics across the India oral anti-diabetic drug market.

High Price of Novel GLP-1 Oral Agents

Monthly therapy with oral Semaglutide costs INR 10,000, deterring widespread uptake in a market where generic Metformin costs under INR 100. Out-of-pocket spending dominates, as 80% of patients lack comprehensive insurance coverage. Clinical trials show 1.56% HbA1c reductions and 5 kg weight loss, yet cost-effectiveness remains negative for most households. Sales therefore remain confined to affluent urban cohorts until patent expiry-led generics emerge post-2026. The India oral anti-diabetic drug market thus balances clinical efficacy gains against affordability ceilings.

Other drivers and restraints analyzed in the detailed report include:

1. PLI Scheme Boosting Diabetes API Output
2. Surge in FDCs & Once-Daily Novel Classes
3. National Price-Control & Trade-Generic Squeeze

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Biguanides anchored by Metformin held 36.85% of India oral anti-diabetic drug market share in 2025. Empagliflozin's patent expiry and rapid price erosion, however, redirected prescribers toward SGLT-2 inhibitors, the fastest-growing class with a 3.79% CAGR to 2031. Sulfonylureas are declining due to hypoglycaemia fears, while DPP-4 inhibitors widened adoption on safety merits. Alpha-glucosidase inhibitors and Meglitinides remain niche. Pharmacogenomic studies show higher prevalence of alleles linked to poor Metformin response among Indian patients, opening avenues for personalised dosing . The India oral anti-diabetic drug market size for SGLT-2 inhibitors is projected to reach USD 611.8 million by 2031, reflecting emerging therapeutic preferences. Novel dual SGLT-1/2 compounds and GLP-1 combinations in the development pipeline may further recalibrate shares as price-sensitive FDCs mature.

A confluence of cardiovascular-renal data and initial price drops is strengthening SGLT-2 molecule positioning. Domestic players with vertically integrated API capacity leverage PLI incentives to undercut imports while ensuring quality compliance. Innovator firms seek differentiation through outcome-based real-world studies, but generics already capture volume prescribing. Net-net, competitive intensity within drug classes is redefining value capture along the India oral anti-diabetic drug market.

Adults generated 67.05% of 2025 prescriptions, yet their CAGR trails at 2.98% because of therapeutic maturity and slowing incidence growth in mid-life cohorts. The geriatric cohort shows a 3.94% CAGR driven by longevity gains and higher multi-morbidities requiring safer agents. India oral anti-diabetic drug market size for geriatrics is estimated at USD 427.6 million in 2025, growing as elderly pensioners turn to affordable Jan Aushadhi generics that cut monthly spend by 70%. Rural elderly patients face access gaps, but teleconsultation pilots in states such as Tamil Nadu are bridging follow-up care.

Polypharmacy challenges accelerate demand for weight-neutral, low-hypoglycaemia formulations. Digital adherence tools customised for large-font interfaces record 18% higher engagement among older users, underpinning incremental sales gains. Meanwhile, paediatric prescriptions remain low volume, yet research into Metformin add-on therapy to mitigate insulin resistance in type 1 adolescents highlights future niche expansion. Overall, demographic evolution ensures a steady patient pipeline within the India oral anti-diabetic drug market.

Complete Report Scope:

• By Drug Class
  • Biguanides
  • Sulfonylureas
  • Meglitinides
  • Thiazolidinediones
  • Alpha-Glucosidase Inhibitors
  • DPP-4 Inhibitors
  • SGLT-2 Inhibitors
  • Others
• By Age Group
  • Adults
  • Pediatric
  • Geriatric
• By Diabetes Type
  • Type 1 Diabetes
  • Type 2 Diabetes
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

List of Companies Covered in this Report:

1. Sun Pharmaceuticals Industries
2. USV Private Ltd.
3. Dr Reddy's Laboratories
4. Cipla
5. Abbott India Ltd.
6. Lupin
7. Glenmark Pharmaceuticals
8. Torrent Pharmaceuticals
9. Zydus Lifesciences
10. Mankind Pharma
11. Alkem Laboratories
12. Takeda Pharma
13. Novo Nordisk
14. Boehringer Ingelheim
15. Eli Lilly and Company
16. AstraZeneca
17. Merck
18. Johnson & Johnson
19. Astellas Pharma
20. Bristol-Myers Squibb
21. Novartis

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support